GlobeNewswire

Medibio Broadens Opportunities with Compatibility to Fitbit Wearable Devices for Mental Health Measurement

Dela

Fitbit joins Apple Watch, Garmin and others allowing users to help process biometric data for an objective view of mental health

SYDNEY, Australia and MINNEAPOLIS, June 13, 2018 (GLOBE NEWSWIRE) -- Medibio Limited  (ASX:MEB) (OTCQB:MDBIF), the world leader in objective measurement technology for mental health, has recently enhanced the compatibility of its mobile app product to accept data from Fitbit devices equipped with heart rate monitors.

The mobile app, named Medibio Inform, allows businesses to offer employees the chance to 'check-in on their mental health' through a comprehensive mental health and wellness program that starts with an employee-facing, Mental Health Check-In campaign. This allows employees of participating businesses using Fitbit devices to assess their mental health using both traditional assessments and biometric measures.  At this time, only Fitbit users that are enrolled in a Mental Health Check-In with their employer have access to use the Inform app.

Via the Inform app, Fitbit users will be able to process specific biometric features to create an objective view of their overall health. Once the user has authorized Medibio to access their Fitbit account, the Inform app then pulls in the sleep, activity and heart rate data that is associated with the user's wearable account. Medibio uses its proprietary platform and algorithms to process the biometric data and reports to the user on a daily basis.

The additional compatibility of Inform working with data from more than 25 million Fitbit wearable technologies, along with already accepted compatibility with nearly 13 million Garmin devices, is timely as the company prepares for the general consumer availability coming later in 2018. 

"We're thrilled to give Fitbit users the ability to monitor their personal, objective biometric data to help manage their overall mental health and well-being," said Jack Cosentino, CEO of Medibio. "With the addition of Fitbit to our portfolio of compatible wearables, this strengthens our footprint in the market, and supports our goal to make our technology accessible to as many consumers as possible."

Medibio's Fitbit-compatible app is available in the App Store and Google Play today for compatible Fitbit devices.   For more information, visit the company's website at www.medibio.com.au.

About Medibio Limited

Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Perth (WA), and Minneapolis, MN (U.S.). Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Further Information: 

 
 Website: www.medibio.com.au
Press Inquiries:
Josh Purdy
Medibio Limited
josh.purdy@medibio.com.au
T: 952-222-0551 ext. 204
M: 612-695-0168
Australian Media Enquiries:
Nicholas Hay
RES Publica
nhay@respublica.com.au
T: +61 475 792 917 // +61 2 8297 1503

 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medibio Limited via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Corline Biomedical AB: Patientrekrytering startar i Renaparin-studie30.11.2018 16:37Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att patientrekrytering i den kliniska fas 1-studien RENAPAIR-01 startar. I studien utvärderas bolagets läkemedelskandidat Renaparin® som är under utveckling för att förbättra utfallet av njurtransplantation. Patienter kommer inledningsvis att rekryteras på Akademiska sjukhuset i Uppsala. När de fyra första patienterna utvärderats inleds också rekrytering på Karolinska Universitetssjukhuset i Huddinge. Beskedet att patientrekrytering startar innebär att förberedelsearbetet inför studiestart är avslutat och att till exempel avtal, initieringsmöte, logistik, provhantering och monitorering är hanterat, samt att godkänt prövningsläkemedel nu finns tillgängligt för rekvirering av kirurgerna på transplantationskliniken i Uppsala för dosering till donatornjurar. När första patient doserats kommer detta meddelas separat. Corline har utvecklat och äger rättigheterna till Renaparin® som administreras direkt till den donerade njuren i

Stillfront: Bytro Labs lanserar en ny version av Supremacy 191427.11.2018 08:00Pressmeddelande

PRESSMEDDELANDE 2018-11-27 Bytro Labs, en studio inom Stillfront Group, lanserar en ny version av Supremacy 1914 Spelutvecklaren Bytro Labs, mest kända för sitt framgångsrika strategispel Call of War, har släppt en ny version av sin klassiska speltitel Supremacy 1914. Dagens lansering är den första av tre milstolpar för den nya versionen av Supremacy 1914 - The Great War som släpps 2019. Den första uppdateringen innehåller en komplett omarbetning av området för spelets community, ett nytt utseende för kartan samt ny 3D-teknologi. I nästa steg kommer Bytro Labs att gå vidare till "true cross platform" där spelet tillgängliggörs för fler plattformar, en strategi som tidigare har varit framgångsrik för titeln Call of War. Supremacy 1914 - The Great War släpps för Android senare i år och i början av 2019 släpps spelet för iOS och Steam. Det tredje och sista steget i lanseringen kommer i mitten av 2019 innehållande en större uppdatering avseende både innehåll och funktion, som färdigställer

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum